Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479 - Wikidata - awgldk - TriplyDB

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

http://www.wikidata.org/entity/Q27487389

about

New era for management of chronic hepatitis C virus using direct antiviral agents: A review Chutes and ladders in hepatitis C nucleoside drug development Preclinical Characterization of JTK-853, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.Inhibition of dengue virus by an ester prodrug of an adenosine analog.PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication New antiviral therapies for chronic hepatitis C Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance.New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.Use of illumina deep sequencing technology to differentiate hepatitis C virus variants.NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase.Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.Molecular epidemiology of hepatitis C infections in Ningxia, China: genotype, phylogeny and mutation analysis Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals.Antiviral therapy for hepatitis C virus: beyond the standard of care.Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs.What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals?Current and future therapies for hepatitis C virus infection: from viral proteins to host targets.Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir.Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.In vitro anti-hepatitis C virus (HCV) resistance selection and characterization.Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system.Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates.

P2860

Q26800050-0B2B698A-5021-48CA-8538-D5923DB4E881 Q26998630-CC7F1674-AF75-479A-B93B-75C8742A22FE Q27679235-655EFF84-1834-4C54-860F-6F7E013EF6B3 Q28541048-2DA888A7-74D0-40AB-B7C4-09FBF59BCD9C Q28542443-56661D7A-5E28-4B85-882C-7DA7081296CE Q28553430-CBC0EC02-010A-40F8-8459-18414EBBBAAC Q34040906-8C9C224D-E8F6-4856-B4C5-43ACAA248973 Q34045313-B1365360-3BF9-4A99-8037-0C39AFBD6790 Q34045444-72DD388D-DEF6-4A15-845F-A81B64495F76 Q34130399-B0BE6B12-74CE-4597-BC76-FF2165207AE0 Q34409020-8231819C-9914-4F01-AB43-069E7F49DE2C Q34489239-8808971C-3FE8-40BF-B570-88789A8DDA8D Q35004972-0D7BC559-6F3E-409A-A623-22A8B35F6EC1 Q35139538-ED281B6E-DB43-49F8-AC89-1D9BF3A8D82F Q35260330-E083AC55-076F-47D1-BE48-E5F2C2115486 Q35650866-8CFC4FBE-72C8-46DE-80C0-6024A5572372 Q35653358-130FC882-6452-47E5-85F1-E43216C7739B Q35806939-1799909D-0957-415E-9907-FF62E824540E Q36583173-3A9D75EA-3ABD-4FD1-81B4-1FBAC28316E6 Q36667165-A4946461-2DFE-4260-8D23-F32BD0B33DD8 Q37350196-DE61B328-1398-423E-8047-E6FE9EDBABC7 Q37855859-9FD8B43B-106D-421C-BC58-AB74A7A851FF Q37855863-8C6D8C1F-5E01-43EE-B2B4-392E6EC0966B Q37926679-7AB1324B-3BD8-47F7-A5C3-84415075AF36 Q37945201-578D0C09-8C97-4758-ABC6-C5219D25DF14 Q37998132-2D41F96D-5713-41EC-8932-985815D4FB58 Q38068357-6B9F685E-9507-49B1-A73B-6464F95C7C73 Q38131681-0B113389-706B-4A85-91C1-70312EDBB92B Q38193551-9638B1DB-0A60-4FF8-8C22-4F0C1F23DECD Q38204368-2015BB33-F5D1-4B2A-B372-FCCDF1744CED Q38283239-C54093E0-6172-4C2F-9B6D-F973036E8A99 Q38427538-8108ED74-19D8-44CF-AD52-689A3548CA03 Q38848491-B8B2FAE0-A1C0-4079-92BA-20D50664CB91 Q38849307-5F0A4DA8-55E4-41EC-B7EE-26B98FF0F23D Q38961245-E87B5C96-C8C5-417A-9C9B-95A74EAEABAA Q39084966-36194853-3A2D-467D-BB6E-3EA5B3B5CEE5 Q39376758-4C457B9E-081E-435E-B83B-961399B1A9FD Q39470512-EFBF4384-E57E-4682-8BF3-14627CA262D1 Q39584985-3ABBA98A-7840-4F91-9174-A867C8C39959 Q39627463-CAF1E3F4-1519-4E3A-BD31-727AF4919CBF

P2860

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

http://www.wikidata.org/entity/Q27487389

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Selected Replicon Variants wit ...... ck Cross-Resistance with R1479

@ast

Selected Replicon Variants wit ...... ck Cross-Resistance with R1479

@en

Selected Replicon Variants wit ...... ck Cross-Resistance with R1479

@nl

type

label

Selected Replicon Variants wit ...... ck Cross-Resistance with R1479

@ast

Selected Replicon Variants wit ...... ck Cross-Resistance with R1479

@en

Selected Replicon Variants wit ...... ck Cross-Resistance with R1479

@nl

prefLabel

Selected Replicon Variants wit ...... ck Cross-Resistance with R1479

@ast

Selected Replicon Variants wit ...... ck Cross-Resistance with R1479

@en

Selected Replicon Variants wit ...... ck Cross-Resistance with R1479

@nl

P1433

Q27487389-DD2130E5-9F8D-4969-9836-ED115B91E0EB

P1476

Q27487389-D63CB9A9-2076-4C77-ABCE-961DF6F406C7

P2093

Q27487389-39351CD2-FE44-4512-8AA1-E38F6BE364BD

Q27487389-487522F0-1CC2-4D50-9132-5A6A10636912

Q27487389-5AD3383A-F500-4F43-A384-8A9A0E997F4D

Q27487389-6015EE1E-EE4A-418E-9FE2-0EE1A7EA6156

Q27487389-61B2BF99-7ABE-4168-AA66-88096A47E237

Q27487389-72ED2F0E-A583-4B6F-B297-142DB5862F8B

Q27487389-7FE726FE-037B-4B98-B0EC-236268722644

Q27487389-8F315F9D-7DFB-4DC5-A1C4-AD3D32EA062A

Q27487389-9574E47A-4BC5-4CFC-B615-57624E37FE04

Q27487389-A8544726-9DDD-4C0C-99F7-F319F3542997

P2860

Q27487389-018A8691-BD0E-497D-9825-AF484F0900D7

Q27487389-022BD5E4-A1D1-47C3-AE5F-9542C092ED61

Q27487389-0C6AE33B-1358-497D-9F45-67F8D2B5D8E3

Q27487389-0DD5B699-24DE-48EC-84F6-AF8FF7EC3B0C

Q27487389-0F4A492B-36AD-4F01-AA72-614CB47392A4

Q27487389-10F31D3E-EC21-42DF-82BD-98C4B370AACD

Q27487389-11B2695F-E7D8-4169-86E5-6292BBEAF34E

Q27487389-12062A6E-DDF1-4C8C-9BE9-D541BBB087DE

Q27487389-12AD2AFE-0722-4418-8BAE-0BF5FDC03E96

Q27487389-13896A84-530C-402D-8A6B-7FCDE8678404

P304

Q27487389-A5780E42-A727-4165-8B3F-121F74112F24

P31

Q27487389-D7F03F76-5F5C-4393-9693-40735629AED3

P3181

Q27487389-E6FEF393-5DC0-46A6-8B99-DF5ADAC8562A

P356

Q27487389-470B3602-7239-42C4-8C59-6EBE9E346281

P407

Q27487389-CC6A166C-41C1-42D1-8B17-E06698B087D5

P433

Q27487389-08809FBD-64E3-410A-A382-5F4284FF7E12

P478

Q27487389-79BB78AC-FB70-4D5A-9598-1BC700B0C138

P577

Q27487389-2C07FD72-E7B6-40A0-BFF7-B2207CD4F0A3

P698

Q27487389-50FF4828-6E8F-4591-B6DC-AB186DF53308

P932

Q27487389-F12A72C3-8065-4F5C-8534-771AB7479A2F

P3181

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Selected Replicon Variants wit ...... ck Cross-Resistance with R1479

@en

P2093

Andre Alker

http://www.w3.org/2001/XMLSchema#string

Friederike Philipp

http://www.w3.org/2001/XMLSchema#string

Han Ma

http://www.w3.org/2001/XMLSchema#string

Hyunsoon Kang

http://www.w3.org/2001/XMLSchema#string

Isabel Najera

http://www.w3.org/2001/XMLSchema#string

Julian Symons

http://www.w3.org/2001/XMLSchema#string

Klaus Klumpp

http://www.w3.org/2001/XMLSchema#string

Mark Smith

http://www.w3.org/2001/XMLSchema#string

Nick Cammack

http://www.w3.org/2001/XMLSchema#string

Nicole Inocencio

http://www.w3.org/2001/XMLSchema#string

P2860

A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties

Characterization of cell lines carrying self-replicating hepatitis C virus RNAs.

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Persistent and transient replication of full-length hepatitis C virus genomes in cell culture

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

Molecular Mechanism of a Thumb Domain Hepatitis C Virus Nonnucleoside RNA-Dependent RNA Polymerase Inhibitor

General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2'-Modified Nucleotide Analogues

Mechanism of Activation of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase

Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759

The Mechanism of Action of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine Involves a Second Metabolic Pathway Leading to -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine 5'-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

P304

4356-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2934230

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.00444-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18838588

http://www.w3.org/2001/XMLSchema#string

P932

2592884

http://www.w3.org/2001/XMLSchema#string